Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure
 

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek to the U.S. Food and Drug Administration.

More...